Concepedia

3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)

Fabrice Barlési, Anne‐Marie C. Dingemans, I. Ou, J.S. Ahn, Luigi De Petris, D.W. Kim, J.C-H. Yang, Benjamin Hughes, H. Léna, Denis Moro‐Sibilot,

European Journal of Cancer · 2015 · 11 citations · 0 references

DOI

Concepts